Antibody-Drug Conjugates and Linker Engineering 2

• 1704 · PDF Method development of purity and assay HPLC method for unstable antibody-drug conjugate linker regulated starting material BCN-OH Yilin Hao, Yujie Guo, Jing Zhuang, Shijuan Xu, Lynn Wang, Xudong Wei, Gengcheng Jack Yang
• 1705 · PDF Compatibility study of routine chromatographic analytical testing of antibody-drug conjugate payload-linkers Tingting Xu, Yupei Deng, Xinsheng Yang, Lynn Wang, Jianqiang Li, Xudong Wei
• 1706 · PDF An integrate comprehensive in vitro and in vivo strategies for antibody drug conjugate development Ismahène Benzaid, Peggy Provent, Aurélie Durgeau, Didier Grillot, Marc Hillairet de Boisferon
• 1707 · PDF ZW191 - a differentiated FRalpha-targeted topoisomerase I antibody drug conjugate active in combination with standard of care drugs Sam Lawn, Andrea Hernández Rojas, Jodi Wong, Araba Sagoe-Wagner, Vincent Fung, Kurt Stahl, Ambroise Wu, Lemlem T. Degefie, Steve Seredick, Pranshul Chauhan, Raffaele Colombo, Jamie R. Rich, Stuart D. Barnscher, Paul A. Moore
• 1708 · PDF Novel DLL3 x B7H3 bispecific ADC demonstrated superior efficacy in preclinical studies Sipeng Li, Chong Liu, Meijun Xiong, Yajun Sun, Zhongsheng Hu, Xinju Gao, Haibo He, Yanwen Feng, Zengyan Mu, Paul H. Song, Gang Qin
• 1709 · PDF BCG042: A promising anti-LILRB4 antibody with ADCC enhancement demonstrates superior efficacy in preclinical models of monocytic AML Jade Hsu, Peiran Li, Yanan Guo
• 1710 ORM-1153: A novel CD123-targeting degrader antibody conjugate with proprietary GSPT1 degrading payload for the treatment of acute myeloid leukemia Dongki Choi, Adam Boutin, Jessica Alves, Sang Hyun Lee, Maysoun Shomali, Anna Skaletskaya, Hangyeol Jeong, MinSoo Kim, Da-Yeong Kim, Khuloud Takrouri, Qinsi Zheng, Nadia Cherkassky, Teresa Mako, Vineetkumar B. Patil, Olaf Christensen, YeonHee Yang, James Palacino
• 1711 · PDF GS002, a novel anti-PD-L1 ADC with targeted cytotoxic delivery and immune checkpoint inhibition Lin Jun, An Deqiang, Song Liwei, Zhu Hongju, Yuan Qiwei, Li Jianshi, Miao Zhongyi, Gao Zhen, Zhou Fang, Wang Xiaolei, Chen Tao, Zhuang Lu, Zhou Kaiyue, Yang Bo, Si Xinjuan, Hu Wenwen, Chang Genqiong, Xu Maosen, Liu Bin, Luo Shun
• 1712 · PDF PA289: A first-in-class prodrug payload with a novel mechanism of action and favorable efficacy/safety profile Alicja Turska, Marc Lee, Bryony Moss, Yong Yi, Iris Britwum, Samuel Barton, Zoë Jukes, Toni Pringle, Adam Lodge, Justyna H. Mysliwy, Jutta Deckert, Robert J. Lutz
• 1713 · PDF STRO-006: An Integrin beta-6-targeting ADC demonstrates favorable safety profile and potent antitumor activity in preclinical solid tumors Kshama A. Doshi, Stephanie Armstrong, Eunice Kim, Dan Shen, Sihong Zhou, Rhoneil Pena, Robert Yuan, Mark Armanini, Brian Vuillemenot, Xiaofan Li, Guifen Xu, Krishna Bajjuri, Miao Wen, Jeff Hanson, Cuong Tran, Amandeep Gakhal, GARRETT GROSS, Gang Yin, Werner Rubas, Genevive Hernandez, Daniel Calarese, Hans-Peter Gerber, Alice Yam
• 1714 First-in-class CHK1 inhibitor antibody-drug conjugate overcomes limitations of current ADC payloads and provides a new option for HER2-positive and TOP1 inhibitor-resistant tumors Thanos D. Halazonetis, Giacomo G. Rossetti, Daniela Carraturo, Michalis Petropoulos, Camilla Trugenberger, Theodoros Rampias, Dennis Gillingham
• 1715 · PDF JS212, a novel bispecific ADC targeting EGFR and HER3, demonstrates superior and broad antitumor activity in preclinical evaluation Wenli Shi, Ning Song, Qiang Fu, Li Ye, Aikun Xia, Mingxing Yang, Jiaming Wang, Xuan Wu, Yue Deng, Yanghua Xu, Xin Wang, Honglin He, Yuyuan Yan, Ziyang Zhong
• 1716 · PDF AT06 is a bispecific antibody drug conjugate targeting DLL3 and SEZ6 with potent activity in small cell lung cancer (SCLC) models Bin Zou, Bryan K. S. Yeung, Nannan Lang
• 1717 · PDF SCR-A014, a novel bispecific ADC targeting B7H3 and DLL3 for SCLC therapy, exhibits potent anti-tumor efficacy Guangcun Cheng, Yayuan Fu, Jiajing Wang, Shuai Wang, Guimei Yang, Chunlei Xia, Xiaoxing Huang, Renhong Tang
• 1718 · PDF RT023, a first-in-class CEACAM5/EGFR targeted bispecific antibody drug conjugate (ADC) in colorectal cancer (CRC) Shuting Huang, Lulu Zhou, Jingjing Cao, Lingli Bi, Qiang Fu, Xuan Wu, Aikun Xia, Jiaming Wang, Yue Deng, Yanghua Xu, Xin Wang, Wenli Shi, Honglin He, Yuyuan Yan, Ziyang Zhong
• 1720 · PDF Preclinical study of BCG039, a Nectin-4×TROP2 bispecific ADC, in urothelial carcinoma and other solid tumor models Frank An, Liu Yang, Chengzhang Shang, Junlan Han, Yi Yang, Frank An
• 1721 · PDF BCG041: A first-in-class bispecific ADC targeting B7-H3 and the proximal membrane region of MUC1 with superior antitumor activity Icy Niu, Peiran Li, Ying Zhu, Yanan Guo
• 1722 Optimal targeting of heterogeneous tumors using highly developable bispecific antibody drug conjugates based on an improved heterodimerization platform and precisely controlled conjugation of a novel payload Dongsop Lee, Younggyu Kong, Seong-Hyun Park, Hyeonseok Jin, Aera Lee, Haerynn Chung, Jungwoo Kim, Jinhoon Jung, Haedueok Jung, Yunjung Um, Youngjee Jeong, Su jin Jung, Haneol Kim, Kyoung-Ho Pyo, Hyungseok Choi, Mi-Kyung Kim
• 1723 Application of clinical stage GlycoConnect® technology to bispecific antibodies yields improved bispecific ADCs in comparison to randomly conjugated bsADCs Lianne Lelieveldt, Nazli Hilal Turkmen, Kinneret Rozales, Maya Wadmany, Anna Kaliakatsou, Floris van Delft, Anette Sommer
• 1724 · PDF NEOK001 (ABL206): A first in class B7-H3xROR1 bispecific ADC demonstrated enhanced efficacy and promising tolerability Min Ji Ko, Junga Kwon, Suyoun Lee, Juhee Kim, Ilhwan Ryu, Junyoung Kim, JaeHyun Eom, Byeong Min Yoo, Hyeon Ji Park, Yong-Gyu Son, Donghoon Yeom, Arim Seo, Byungje Sung, Jinwon Jung, Jinhyung Ahn, Weon-Kyoo You, Sang Hoon Lee
• 1725 Dual modality of EpiTAC bispecific degrader ADCs combines c-MET degradation with cytotoxic payload delivery to overcome limitations of current c-MET-targeted therapies Lisa Marshall, Jonathan Sitrin, Kenneth Ng, Shruti Yadav, May Dayao, Hai Tran, Josef Gramespacher, Jacob Cohen, Kimberly Hoi, Zhong Huang, Noah Solomon, John Coan, Andy Goodrich, Adison McLaggan, Sarah Yan, Brian Hillier, Danica Manalo-Hebert, Lichao Zhang, Maia Vinogradova, Isaac J. Rondon, Shyra J. Gardai
• 1726 · PDF NEOK002 (ABL209): Redesigning an EGFRxMUC1 bispecific TOP1i ADC with promising anti-tumor activity and enhanced therapeutic window Bora Lee, Hyeon Ji Park, Byeong Min Yoo, Hangil Kim, Junyoung Kim, Arim Seo, Youngeun Hong, Donghoon Yeom, Yong-Gyu Son, Jaehyun Eom, Byungje Sung, Jinhyung Ahn, Jinwon Jung, Weon-Kyoo You, Sang Hoon Lee
• 1727 · PDF Dual targeting of HER2 and AXL by an eKiH-engineered bispecific ADC to overcome resistance in solid tumors Kyoung-Ho Pyo, Seong-Hyun Park, Dongsop Lee, Haneol Kim, Younggyu Kong, Younggeun Lee, Hojin Yeom, Sowon Aum, Sun Hee Park, Huijo Oh, Cheyeon Kim, Hyeonseok Jin, Aera Lee, Hojeong Hong, Ju Hwan Kim, Hyungseok Choi, Mi-Kyung Kim, Taedong Han
• 1728 · PDF Overcoming target heterogeneity in gastric cancer with an eKiH-engineered CLDN18.2×HER2 bispecific ADC Kyoung-Ho Pyo, Seong-Hyun Park, Dongsop Lee, Haneol Kim, Younggyu Kong, Younggeun Lee, Hojin Yeom, Sowon Aum, Sun Hee Park, Huijo Oh, Cheyeon Kim, Hyeonseok Jin, Aera Lee, Hojeong Hong, Ju Hwan Kim, Hyungseok Choi, Mi-Kyung Kim, Taedong Han
• 1729 · PDF OBI-904, a next-generation nectin-4-targeting exatecan ADC, demonstrates enhanced cytotoxicity and overcomes enfortumab vedotin resistance Yuan-Liang Wang, Chi-Huan Lu, Woan-Eng Chan, Shin-Jin Lin, Ting-Yu Chang, Hong-Syuan Lin, Wei-Jhen Huang, Ya-Chi Chen
• 1730 · PDF Guide-effector bsADCs: Driving co-endocytosis for enhanced payload delivery Wei-Jhen Huang, Woan Eng Chan, Meng-Hsin Liu, Yueh Chin Wu, Ya-Chi Chen
• 1731 · PDF Hydrophilicity-enhanced linker technology enables site-specific degrader-antibody conjugates with improved stability and enhanced activity Yu-Hung Chen, Wei-Chien Tang, Chi-Dian Lu, Hung-Yi Lin, Wei-Jhen Huang, Nan-Hsuan Wang, Ya-Chi Chen, Teng-Yi Huang

在完整检索应用中浏览本分会场 →